Cardinal health awarded fda funding to assess real world evidence results against clinical trials

Dublin, ohio, oct. 28, 2021 /prnewswire/ -- cardinal health (nyse: cah) announced today it has been awarded a $750,000 contract by the u.s. food and drug administration (fda) to implement an 18-month real world evidence (rwe) study as part of the agency's efforts to advance the applicability of rwe in regulatory decision-making. the funding, which will support the project "assessment of a novel methodology for endpoints assessing response to lymphoma treatment in real-world studies," will evaluate the accuracy of real-world data (rwd) for lymphoma tumor response compared to blinded independent central review, the gold standard in randomized clinical trials.
CAH Ratings Summary
CAH Quant Ranking